1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (1087)
  2. Meeting Abstract (890)
  3. Review (52)
  4. Book Section (46)
  5. Editorial (35)
  6. Guidelines (21)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (288)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (41)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (450)
  2. Gynecologic Oncology (418)
  3. International Journal of Gynecological Cancer (154)
  4. Annals of Oncology (116)
  5. Clinical Cancer Research (67)
  6. Cancer Research (55)

More Publications

Publishers
  1. Elsevier Inc. (542)
  2. American Society of Clinical Oncology (489)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (168)
  5. Oxford University Press (143)
  6. Nature Publishing Group (86)

More Publishers

Results (2146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer
    Meeting Abstract

    O'Cearbhaill, R. E.; Hyman, D. M.; Tew, W. P.; Iasonos, A.; Cangemi, N. A.; Aghajanian, C.; Bell-Mcguinn, K. M.; Makker, V.; Hensley, M. L.; Konner, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study
    Meeting Abstract

    Myers, A. P.; Filiaci, V. L.; Zhang, Y. P.; Pearl, M.; Behbakht, K.; Makker, V.; Hanjani, P.; Zweizig, S.; Burke, J. J.; Downey, G.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Neoadjuvant chemotherapy (NACT) selection for advanced stage ovarian cancer (AOC) at a comprehensive cancer center
    Meeting Abstract

    Mueller, J. J.; Alvi, F. A.; El Haraki, A. S.; Eriksson, A. G.; Zhou, Q.; Iasonos, A.; O'Cearbhaill, R. E.; Chi, D.; Abu Rustum, N.; Zivanovic, O.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
    Meeting Abstract

    Monk, B. J.; Grisham, R. N.; Marth, C.; Banerjee, S. N.; Hilpert, F.; Coleman, R. L.; Pujade-Lauraine, E.; Pignata, S.; Mirza, M. R.; Oza, A. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Outcomes of stage IA polyp-limited vs endometrium-limited epithelial high grade endometrial carcinoma (EMC)
    Meeting Abstract

    Liang, L.; Perez, A. R.; Cangemi, N. A.; Zhou, Q.; Iasonos, A.; Alektiar, K. M.; Abu Rustum, N.; Makker, V.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D)
    Meeting Abstract

    Hyman, D. M.; Sill, M.; Cho, J. K.; Lankes, H. A.; Piekarz, R.; Hensley, M. L.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
    Meeting Abstract

    Grisham, R. N.; Gordon, M. S.; Harb, W. A.; Aghajanian, C.; McMeekin, D. S.; McKinley, K.; Anderson, L. R.; Chavira, R.; Christy-Bittel, J.; Barrett, E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS)
    Meeting Abstract

    Demetri, G. D.; von Mehren, M.; Jones, R. L.; Hensley, M. L.; Schuetze, S.; Staddon, A. P.; Milhem, M. M.; Elias, A. D.; Ganjoo, K. N.; Tawbi, H. A. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
    Meeting Abstract

    Bell-Mcguinn, K. M.; Brady, W. E.; Schilder, R. J.; Fracasso, P. M.; Moore, K. N.; Walker, J. L.; Duska, L. R.; Mathews, C. A.; Chen, A.; Shepherd, S. P.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study-Analysis of patient reported outcomes (PRO) on chemotherapy randomization
    Meeting Abstract

    Basen-Engquist, K.; Huang, H. Q.; Herzog, T. J.; Armstrong, D. K.; Sabbatini, P.; Walker, J. L.; Kim, B. G.; Fujiwara, K.; Tewari, K. S.; O'Malley, D. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save